Why the study?
Does lovastatin reduce the angiographic progression of coronary atherosclerosis and new lesion formation in smokers with coronary disease and hypercholesterolemia?
Population
331 patients with coronary atherosclerosis shown on a recent angiogram and fasting cholesterol levels…
Comparison
Lovastatin at a mean dose of 36 mg/d vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
2 years
Authors
Loading...
Supports statin use to slow atherosclerosis in smokers with CAD; extends lipid-lowering trial evidence to this high-risk subgroup.
Does lovastatin reduce the angiographic progression of coronary atherosclerosis and new lesion formation in smokers with coronary disease and hypercholesterolemia?
Smoking accelerates angiographic progression of coronary atherosclerosis, but treatment with lovastatin significantly slows this progression and prevents new lesion formation in smokers.
Waters et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: